|
2025
|
G/S
|
Pharmaceutical preparations |
|
2024
|
G/S
|
Pharmaceutical preparations; Pharmaceutical preparations for the treatment of Duchenne Muscular D... |
|
|
Invention
|
Crystalline substituted pyrazines as pgi2 receptor agonists.
A main object of the present invent... |
|
|
G/S
|
Medical and pharmaceutical preparations, for the treatment of Duchenne Muscular Dystrophy, both p... |
|
|
Invention
|
Antisense nucleic acids.
The present invention provides a pharmaceutical composition which cause... |
|
|
Invention
|
Cell population of human urine-derived cells, and cell population of myotubes induced therefrom a... |
|
|
Invention
|
Antisense oligonucleotide targeting atn1 mrna or pre-mrna.
The present invention provides an ant... |
|
|
Invention
|
Method for producing guaiazulene. The present invention relates to a method for producing guaiazu... |
|
|
Invention
|
Antisense nucleic acids.
The present invention provides an oligomer which allows exon 45 skippin... |
|
|
Invention
|
Measuring container.
A measuring container comprises a storage container and a storage section s... |
|
2023
|
Invention
|
Compound serving as ddr1 kinase inhibitor, and medicine. Provided is a compound having DDR1 inhib... |
|
|
Invention
|
Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscul... |
|
|
Invention
|
Flow liquid separation device, flow liquid separation system, and production method for compound ... |
|
|
Invention
|
Solid dispersion, pharmaceutical preparation containing solid dispersion, and methods respectivel... |
|
|
G/S
|
Medical and pharmaceutical preparations, for the treatment of myelofibrosis, eosinophilic granulo... |
|
|
Invention
|
Pharmaceutical composition. The present invention provides a pharmaceutical composition containin... |
|
|
Invention
|
Antisense oligonucleotide targeting tdp-43 mrna or pre-mrna. In the description of the present in... |
|
|
Invention
|
Compound serving as ddr1 kinase inhibitor, and medicine. The present invention provides a compoun... |
|
|
Invention
|
Crystals.
A main object of the present invention is to provide new crystals of (S)-N2-[1-(4-fluo... |
|
|
Invention
|
Crystalline substituted pyrazines as pgi2 receptor agonists. A form-II crystal of Compound B, whi... |
|
|
Invention
|
Method for estimating microbial growth rate in food, method for evaluating shelf life of food, an... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations for the treatment of Duchenne muscular d... |
|
|
Invention
|
Nucleic acid having carrier peptide linked thereto. In the present description, there are provide... |
|
|
Invention
|
Antiviral antisense oligomer. The present specification provides an antisense oligomer that has a... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of duchenne muscular ... |
|
2022
|
Invention
|
Indazole compound and pharmaceutical. The present invention provides a compound indicated by gene... |
|
|
Invention
|
Method for producing oligonucleic acid compound. The present invention relates to a method for pr... |
|
|
Invention
|
Antisense oligonucleotide targeting atn1 mrna or pre-mrna. The present invention provides an anti... |
|
|
Invention
|
Antisense nucleic acids.
The present invention provides an oligomer which efficiently enables to... |
|
|
Invention
|
Antiviral antisense oligonucleotide.
The present specification provides an antisense oligonucleo... |
|
|
Invention
|
Antiviral antisense oligonucleotide. In the present description, provided are an antisense oligon... |
|
|
Invention
|
Heat-resistant mold growth inhibitor, food and drink in which growth of heat-resistant mold is in... |
|
|
Invention
|
Antisense nucleic acid inducing skipping of exon 51. The present specification provides a drug th... |
|
|
Invention
|
Nephrotoxicity reducing agent.
In one embodiment, the object of the present invention is to prov... |
|
|
Invention
|
Precipitation suppressing agent.
In one embodiment, the object of the present invention is to pr... |
|
|
Invention
|
Nephrotoxicity reducing agent. [Problem] In one embodiment, the present invention addresses the p... |
|
|
Invention
|
Precipitation suppressing agent. [Problem] In an embodiment, the present invention addresses the ... |
|
|
Invention
|
Combination of antisense oligomers.
Herein, a combination of antisense oligomers or pharmaceutic... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of Duchenne muscular ... |
|
|
Invention
|
Antiviral nucleic acid.
An object of the present invention is to provide an antiviral nucleic ac... |
|
|
Invention
|
Method for producing oligonucleic acid compound.
The present invention relates to a method for p... |
|
|
Invention
|
Therapeutic agent for gait disturbance.
The present invention relates to a therapeutic agent for... |
|
|
Invention
|
Pill container.
A pill container includes a plurality of pill accommodation portions each extend... |
|
|
Invention
|
Therapeutic agent for high-risk myelofibrosis. The present invention relates to a novel therapeut... |
|
2021
|
Invention
|
Antisense nucleic acid inducing skipping of exon 51.
The present specification provides a drug t... |
|
2020
|
Invention
|
Antisense nucleic acid that induces skipping of exon 50.
The present specification provides a dr... |
|
|
Invention
|
Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome.
The ... |
|
|
Invention
|
Antitumor drug for use in combination with immune checkpoint inhibitor.
The present invention re... |
|
|
Invention
|
Antisense nucleic acid enabling exon skipping.
The present specification provides an antisense o... |
|
|
Invention
|
Compound and composition as pdgf receptor kinase inhibitor.
An object of the present invention i... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of Duchenne Muscular Dystrophy |
|
2018
|
G/S
|
Pharmaceutical preparations, namely nucleic acid reagents for medical scientific research; Pharma... |
|
|
G/S
|
Pharmaceutical preparations, namely nucleic acid diagnostic reagents for medical purposes; Pharma... |
|
|
G/S
|
Medical and pharmaceutical preparations for the treatment of Duchenne Muscular Dystrophy, both pr... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of myelofibrosis; Pharmaceutical preparations for t... |
